Comments
Aurobindo Pharma’s scrip gained 3.53 per cent on the BSE on Monday to end at ₹1,373.85 on the share buyback move.
The board of directors of the Hyderabad-based company will be meeting on July 18 to consider a proposal for buyback of the fully paid-up equity shares of the company in accordance with the applicable provisions under the Companies Act, 2013, the company informed the BSE.
The company has reported a net profit of ₹909 crore in the fourth quarter ending March 31, 2024, as against ₹506 crore in the same quarter last year, showing a growth of 79.6 per cent. It registered a revenue of ₹7,580 crore in the quarter (₹6,473 crore), showing a growth of 17.1 per cent.
For FY24, it reported a net profit of ₹3,173 crore (₹1,927 crore) on a revenue of ₹29,002 crore (₹24,855 crore).
- Also read: HUL sells Pureit to AO Smith for ₹601 crore
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.